Special Issue

Non-Psychotropic Phytocannabinoids: A New Source of Drugs

Message from the Guest Editor

One of the most controversial and debated plants in history is Cannabis sativa. Human societies have considered C. sativa as a food, a medicine, and for religious purposes. All the virtues of *C. sativa* are due to the multitude of its chemical components, such as phytocannabinoids, terpenoids, flavonoids, and alkaloids, that have been extracted, purified, and tested in various preclinical models. Trans- Δ -9tetrahydrocannabinol (D9-THC) is the phytocannabinoid responsible for the psychotropic effects of C. sativa, but in recent years, in many parts of the world, C. sativa cultivars called "light", which contain low levels of D9-THC and high levels of non-psychotropic phytocannabinoids such as cannabidiol (CBD), have been cultivated. This Special Issue will collect manuscripts on the biosynthetic, extractive, and analytical aspects of phytocannabinoids without psychotropic activity. Furthermore, particular interest will be given to the potential therapeutic applications of new characterized phytocannabinoids.

Guest Editor

Prof. Dr. Andrea Mastinu Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, 25123 Brescia, Italy

Deadline for manuscript submissions

closed (31 May 2023)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



mdpi.com/si/33536

Molecules Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 molecules@mdpi.com

mdpi.com/journal/

molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



molecules



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).